HA14-1

HA14-1 is a Bcl-2/Bcl-XL antagonist. HA14-1 binds the designated pocket on Bcl-2 with the IC50 of ≈9 μM in competing with the Bcl-2 binding of Flu-BakBH3, and inhibits its function.

Product Specifications

CAS Number

[65673-63-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/HA14-1.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : ≥ 50 mg/mL

Smiles

CCOC(C1=C(N)OC2=CC=C(Br)C=C2[C@@]1([H])[C@H](C#N)C(OCC)=O)=O

Molecular Formula

C17H17BrN2O5

Molecular Weight

409.23

Precautions

H302, H315, H319, H335

References & Citations

[1]Wang JL, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2000 Jun 20;97 (13) :7124-9.|[2]Kessel D, et al. Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA14-1. Cancer Lett. 2007 May 8;249 (2) :294-9.|[3]Manero F, et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res. 2006 Mar 1;66 (5) :2757-64.